Table 4 Profiles of fluoroquinolone and second-line injectable drug resistance identified by phenotypic and molecular assays.
DST | Mutations detected by the Array | GenoType MTBDRsl | Gene sequencing | No. of isolate (%) |
|---|---|---|---|---|
FQ | ||||
S | WT | WT | — | 94 (53.4) |
R | WT | WT | WT | 4 (2.3)* |
— | gyrA G88C M1 | — | — | 0 |
R | gyrA A90V M1 | ∆ gyrA WT 2 | — | 16 (9.1) |
R | gyrA S91P M1 | ∆ gyrA WT 2 | — | 3 (1.7) |
S | gyrA S91P M1 | ∆ gyrA WT 2 | gyrA S91P | 1 (0.6)* |
R | gyrA D94G M1 | ∆ gyrA WT 3, MUT 3C | — | 32 (18.2) |
R | gyrA D94A M2 | ∆ gyrA WT 3, MUT 3 A | — | 4 (2.3) |
R | gyrA D94N M3 | ∆ gyrA WT 3, MUT 3B | — | 17 (9.7) |
R | gyrA D94H M4 | ∆ gyrA WT 3, MUT 3D | — | 2 (1.1) |
R | gyrA D94Y M5 | ∆ gyrA WT 3 | — | 3 (1.7) |
KM/AM/CAP | ||||
SSS | WT | WT | — | 99 (56.3) |
SSR | WT | WT | WT | 2 (1.1)* |
RRR | rrs A1401G M1 | ∆ rrs WT 1, MUT 1 | — | 32 (18.2) |
RRS | rrs A1401G M1 | ∆ rrs WT 1, MUT 1 | rrs A1401G | 21 (11.9)* |
RSR | rrs C1402T M1 | ∆ rrs WT 1 | — | 2 (1.1) |
RRR | rrs G1484T M1 | ∆ rrs WT 2, MUT 2 | — | 2 (1.1) |
SRS | eis G-10A M1 | ∆ eis WT 2 | — | 5 (2.8) |
— | eis G-10C M2 | — | — | 0 |
RSS | eis C-12T M1 | ∆ eis WT 2 | — | 2 (1.1) |
SSR | eis C-12T M1 | ∆ eis WT 2 | eis C-12T | 1 (0.6)* |
RSS | eis C-14T M1 | ∆ eis WT 2, MUT 1 | — | 3 (1.7) |
RSR | eis C-14T M1 | ∆ eis WT 2, MUT 1 | — | 1 (0.6) |
RRS | eis C-14T M1 | ∆ eis WT 2, MUT 1 | — | 1 (0.6) |
RSS | eis G-37T M1 | eis MUT 1 | eis G-37T/ WT | 1 (0.6)* |
RSS | eis G-37T M1 | ∆ eis WT 1 | — | 2 (1.1) |
